Zoetis Inc. (NYSE:ZTS) Shares Purchased by Oakworth Capital Inc.

Oakworth Capital Inc. raised its stake in Zoetis Inc. (NYSE:ZTS) by 345.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 6,488 shares of the company’s stock after buying an additional 5,031 shares during the quarter. Oakworth Capital Inc.’s holdings in Zoetis were worth $1,281,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the stock. Enterprise Financial Services Corp lifted its position in Zoetis by 2.3% in the first quarter. Enterprise Financial Services Corp now owns 2,446 shares of the company’s stock valued at $407,000 after buying an additional 55 shares during the last quarter. CreativeOne Wealth LLC increased its stake in Zoetis by 0.4% during the second quarter. CreativeOne Wealth LLC now owns 12,833 shares of the company’s stock worth $2,210,000 after purchasing an additional 57 shares during the period. River Street Advisors LLC increased its stake in Zoetis by 3.4% during the fourth quarter. River Street Advisors LLC now owns 1,757 shares of the company’s stock worth $347,000 after purchasing an additional 58 shares during the period. Perigon Wealth Management LLC increased its stake in Zoetis by 0.3% during the fourth quarter. Perigon Wealth Management LLC now owns 23,581 shares of the company’s stock worth $4,654,000 after purchasing an additional 59 shares during the period. Finally, TFC Financial Management Inc. increased its stake in Zoetis by 3.3% during the third quarter. TFC Financial Management Inc. now owns 1,918 shares of the company’s stock worth $334,000 after purchasing an additional 61 shares during the period. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Performance

ZTS stock traded down $1.24 during trading on Wednesday, reaching $151.78. 2,390,289 shares of the company’s stock were exchanged, compared to its average volume of 2,952,470. The company has a quick ratio of 2.00, a current ratio of 3.36 and a debt-to-equity ratio of 1.32. The firm has a market cap of $69.42 billion, a PE ratio of 30.18, a P/E/G ratio of 2.29 and a beta of 0.85. The company’s fifty day moving average price is $178.25 and its 200-day moving average price is $180.59. Zoetis Inc. has a 1-year low of $148.48 and a 1-year high of $201.92.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Tuesday, February 13th. The company reported $1.24 earnings per share for the quarter, missing the consensus estimate of $1.32 by ($0.08). The firm had revenue of $2.21 billion during the quarter, compared to analyst estimates of $2.19 billion. Zoetis had a net margin of 27.43% and a return on equity of 51.25%. The company’s quarterly revenue was up 8.5% compared to the same quarter last year. During the same quarter last year, the company earned $1.15 EPS. On average, research analysts expect that Zoetis Inc. will post 5.8 EPS for the current fiscal year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 4th. Stockholders of record on Friday, April 19th will be given a dividend of $0.432 per share. This represents a $1.73 dividend on an annualized basis and a dividend yield of 1.14%. The ex-dividend date of this dividend is Thursday, April 18th. Zoetis’s dividend payout ratio (DPR) is presently 34.12%.

Insider Transactions at Zoetis

In related news, EVP Roxanne Lagano sold 923 shares of the company’s stock in a transaction on Thursday, January 18th. The stock was sold at an average price of $191.43, for a total transaction of $176,689.89. Following the transaction, the executive vice president now directly owns 17,569 shares of the company’s stock, valued at $3,363,233.67. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold 2,209 shares of company stock valued at $408,453 over the last three months. Company insiders own 0.15% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Piper Sandler restated an “overweight” rating and set a $195.00 target price (down from $220.00) on shares of Zoetis in a research note on Tuesday. The Goldman Sachs Group boosted their price target on Zoetis from $190.00 to $226.00 and gave the stock a “buy” rating in a research report on Wednesday, January 17th. StockNews.com lowered Zoetis from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 20th. Stifel Nicolaus dropped their price objective on Zoetis from $215.00 to $195.00 and set a “buy” rating on the stock in a report on Tuesday, April 2nd. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $230.00 price target on shares of Zoetis in a report on Tuesday, December 19th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, Zoetis presently has a consensus rating of “Buy” and an average price target of $221.75.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.